nature portfolio

Corresponding author(s):	Weimin Li
Last updated by author(s):	Jun 27, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				
C 4	- ~	+-	$\cdot \sim +$	ics
71	_		\sim 1	11 <

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$oxed{\boxtimes}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

No special software or code was used to collect the data.

Data analysis

We used the platform of PyTorch with one Nvidia Tesla V100 GPU for deep learning system design, IBM SPSS 26.0 for statistical analyses, GraphPad Prism 9, Origin 2021 and Adobe Illustrator 2023 for figure plot.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The relevant images supporting the experiment in this paper are from the Medical Checkup cohort (N=45,064) and the Mobile Screenning Cohort (N=14,437). The full datasets are protected because of privacy issues and regulation policies in West China Hospital of Sichuan University.

and the second s			and the second s			
Research involving	human na	articinanta	thair data	arhial	اممنمما	l mantarial
RESEATED INVOIVING	numan na	armenbanis	THEIL DATA		ואווענו	marena
Trescarent introducing	TIGITIGH PC	ai ticiparita,	tileli aata,		σ_{Σ}	IIIacciia

	studies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> d <u>race, ethnicity and racism</u> .				
Reporting on sex and ge	ender Sex was equally considered in the study design. The proposed algorithm could be suitable for people of all sexes.				
Reporting on race, ethni other socially relevant groupings	icity, or Information on race, ethnicity, or other socially relevant grouping was not collected.				
Population characteristic	A total of 45,064 participants from the Medical Checkup Cohort and 14,437 participants in a Mobile Screening Cohort with lung nodules were included in the study. In primary dataset, their median age was 47 years, 58.7% were men and 71.5% had never smoked. Meanwhile, the mean age was 57 years in the independent testing dataset with a majority of 64.5% females and 75.3% non-smokers. The more details of population characteristics were provided in Supplementary Table 1.				
Recruitment	This was a retrospective study with no specific recruitment requirements.				
Ethics oversight	This study was approved by the Research Ethics Committee in West China Hospital of Sichuan University.				
Note that full information on	the approval of the study protocol must also be provided in the manuscript.				
Eiold sposifi	croporting				
Field-specifi	<u>creporting</u>				
Please select the one belo	w that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of the docur	ment with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life sciences	s study design				
	ose on these points even when the disclosure is negative.				
Sample size The sa	mple sizes for the primary dataset and independent testing dataset are 45,064 and 14,437 respectively.				
nodule	were excluded from study enrollment if they met any of the following criteria: (1) received any surgical resection of pulmonary fore enrollment, (2) combined with other serious lung diseases such as pulmonary fibrosis and bronchiectasis, and (3) chest CT lity failed to meet the required standards, CT volumes with <50 slices or patients with no qualifying volumes.				
Replication Replica	ation was not relevant. We used independent cohorts.				
Randomization We rai	mly splited primary dataset as training and internal testing sets in Figure S1, where the internal testing set accounted for 20%.				
Blinding The pr	ocess was blinding. During image processing, all images were first de-identified to remove any patient related information.				
-					
_					
Reporting to	or specific materials, systems and methods				
We require information from	authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,				
system or method listed is rel	levant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Matarials & oversing	antal systems. Mathods				
Materials & experiments					
n/a Involved in the study					
Antibodies Eukaryotic cell line					
I_					
Palaeontology and Animals and other					
Animals and other Clinical data	OI Ballishis				
Dual use research	of concern				
Plants	51 COTICCTIT				
MILL FIGURE					